Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: A propensity score matched analysis

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 3, 2015, Pages 505-516

  Smith, Graham D ^a   Pickles, Tom ^b   Crook, Juanita ^c   Martin, Andre Guy ^d   Vigneault, Eric ^d   Cury, Fabio L ^e   Morris, Jim ^b   Catton, Charles ^f   Lukka, Himu ^g   Warner, Andrew ^h   Yang, Ying ⁱ   Rodrigues, George ^a,h  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c KELOWNA GENERAL HOSPITAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g JURAVINSKI CANCER CENTRE   (Canada)

^h LONDON HEALTH SCIENCES CENTRE   (Canada)

ⁱ UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOINFORMATICS; DISEASES; DOSIMETRY; FAILURE (MECHANICAL); HOSPITAL DATA PROCESSING; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; UROLOGY;

BIOCHEMICAL FAILURE; EXTERNAL BEAM RADIATION THERAPY; HIGH-DOSE RATE BRACHYTHERAPY; INTERMEDIATE RISKS; LOW DOSE RATE BRACHYTHERAPY; METHODS AND MATERIALS; PRIMARY RADIATIONS; PROPENSITY SCORE MATCHING;

RISK ASSESSMENT;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; INTERMEDIATE RISK PATIENT; INTERMETHOD COMPARISON; LOW ENERGY RADIATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROPENSITY SCORE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; ADVERSE EFFECTS; BLOOD; CANADA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION DOSE; REGRESSION ANALYSIS; RISK; VERY ELDERLY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CANADA; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK;

EID: 84923292688     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.11.018     Document Type: Article

References (63)

1. M. Keyes, J. Crook, and G. Morton Treatment options for localized prostate cancer Can Fam Physician 59 2013 1269 1274
2. H. Lukka, P. Warde, and T. Pickles Controversies in prostate cancer radiotherapy: Consensus development Can J Urol 8 2001 1314 1322
3. G. Rodrigues, P. Warde, and T. Pickles Pre-treatment risk stratification of prostate cancer patients: A critical review Can Urol Assoc J 6 2012 121 127
4. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomized controlled trial Lancet Oncol 8 2007 475 487
5. A. Creak, E. Hall, and A. Horwich Randomized pilot study of dose escalation using conformal radiotherapy in prostate cancer: Long-term follow-up Br J Cancer 109 2013 651 657
6. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
7. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09 J Clin Oncol 28 2010 1106 1111
8. V. Beckendorf, S. Guerif, and E. Le Prise 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial Int J Radiat Oncol Biol Phys 80 2011 1056 1063
9. W.D. Heemsbergen, A. Al-Mamgani, and A. Slot Long-term results of the Dutch randomized prostate cancer trial: Impact of dose-escalation on local, biochemical, clinical failure, and survival Radiother Oncol 110 2014 104 109
10. D.P. Dearnaley, G. Jovic, and I. Syndikus Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomized controlled trial Lancet Oncol 15 2014 464 473
11. J.R. Santhya, I.R. Davis, and J.A. Julian Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 2005 1192 1199
12. P.J. Hoskin, A.M. Rojas, and P.J. Bownes Randomized trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localize prostate cancer Radiother Oncol 103 2012 217 222
13. A. Loblaw The value of randomized trials for prostate cancer management Lancet Oncol 15 2014 374 375
14. D.C. Beyer, and D.G. Brachman Failure-free survival following brachytherapy alone for prostate cancer: Comparison with external beam radiotherapy Radiother Oncol 57 2000 263 267
15. M.J. Burdick, C.A. Reddy, and J. Ulchaker Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer Int J Radiat Oncol Biol Phys 73 2009 1439 1445
16. J. Coen, A. Zietman, and C. Rossi Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: A case-matched analysis Int J Radiat Biol Phys 81 2012 e25 e31
17. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for localized prostate cancer JAMA 280 1998 969 974
18. C.A. Da Silva Franca, S.L. Vieira, and A.C. Carvalho Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy Brachytherapy 9 2010 307 312
19. I. Deutsch, M.J. Zelefsky, and Z. Zhang Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT Brachytherapy 9 2010 313 318
20. R. Khor, G. Duchesne, and K.H. Tai Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer Int J Rad Oncol Biol Phys 85 2013 679 685
21. L. Kestin, A. Martinez, and J. Stromberg Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer J Clin Oncol 18 2000 2869 2880
22. P.A. Kupelian, L. Potters, and D. Khuntia Radical prostatectomy, external beam radiotherapy < 72 Gy, external beam radiotherapy > 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
23. T. Pickles, M. Keyes, and W.J. Morris Brachytherapy or conformal external radiotherapy for prostate cancer: A single-institution matched pair analysis Int J Radiat Oncol Biol Phys 76 2010 43 49
24. M. Pinkawa, M.D. Piroth, and R. Holy Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer Radiother Oncol 96 2010 25 29
25. W. Wong, S. Vora, and S. Schild Radiation dose escalation for localized prostate cancer: Intensity-modulated radiotherapy versus permanent transperineal brachytherapy Cancer 115 2009 5596 5606
26. E.H. Zhou, R.J. Ellis, and E. Cherullo Radiotherapy and survival in prostate cancer patients: A population-based study Int J Radiat Oncol Biol Phys 73 2009 15 23
27. T.N. Eade, E.M. Horwitz, and K. Ruth A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity modulated radiation therapy or 125I permanent implant Int J Radiat Oncol Biol Phys 71 2008 338 345
28. G. Goldner, R. Potter, and J. Battermann Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients Strahlenther Onkol 188 2012 305 310
29. V. Gondi, I. Deutsch, and M. Mansukhani Intermediate-risk localized prostate cancer in the PSA era: Radiotherapeutic alternatives Urology 69 2007 541 546
30. E.A. Klein, J. Ciezki, and P.A. Kupelian Outcomes for intermediate risk prostate cancer: Are there advantages for surgery, external radiation, or brachytherapy? Urol Oncol 27 2009 67 71
31. M.L. Pe, E.J. Trabulsi, and R. Kedika Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT Urology 73 2009 1328 1335
32. A. Vassil, E. Murphy, and C. Reddy Five-year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation Urology 76 2010 1251 1257
33. M. Zelefsky, Y. Yamada, and X. Pei Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer Urology 77 2011 986 993
34. M. Bolla, L. Collette, and L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial Lancet 360 2002 103 108
35. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
36. J.W. Denham, A. Steigler, and D.S. Lamb Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the RTOG 96.01 randomized trial Lancet Oncol 12 2011 451 459
37. C.U. Jones, D. Hunt, and D.G. McGowan Radiotherapy and short-term androgen deprivation for localized prostate cancer N Engl J Med 365 2011 107 118
38. C.A. Lawton, K. Winter, and K. Murray Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Rad Onc Biol Phys 49 2001 937 946
39. P. Austin Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: A systematic review and suggestions for improvement J Thorac Cardiovasc Surg 134 2007 1128 1135
40. P.R. Rosenbaum, and D.B. Rubin The central role of the propensity score in observational studies for causal effects Biometrika 70 1983 41 55
41. P.R. Rosenbaum, and D.B. Rubin Reducing bias in observation studies using subclassification on the propensity score J Am Stat Assoc 79 1984 516 524
42. Y.N. Wong, N. Mitra, and G. Hudes Survival associated with treatment vs observation of localized prostate cancer in elderly men JAMA 296 2006 2683 2693
43. A.B. Chen, B.A. Neville, and D.J. Sher Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation J Clin Oncol 29 2011 2305 2311
44. N. Verstegen, J. Ooosterhuis, and D. Palma Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): Outcomes of a propensity score-matched analysis Ann Oncol 24 2013 1543 1548
45. P.A. Ganz, L. Kwan, and A.L. Stanton Physical and psychosocial recovery in the year after primary treatment of breast cancer J Clin Oncol 29 2011 1101 1109
46. E.S. O'Connor, D.Y. Greenblatt, and N.K. LoConte Adjuvant chemotherapy for stage II colon cancer with poor prognostic features J Clin Oncol 29 2011 3381 3388
47. G. Rodrigues, J. Zindler, and A. Warner Propensity-score matched pair comparison of whole brain with simulation-in-field boost radiotherapy and stereotactic radiosurgery Radiother Oncol 106 2013 206 209
48. G. Rodrigues, H. Lukka, and P. Warde The prostate cancer risk stratification project: Database construction and risk stratification outcome analysis J Natl Compr Canc Netw 12 2014 60 69
49. G. Rodrigues, H. Lukka, and P. Warde The prostate cancer risk stratification (ProCaRS): Recursive partitioning risk stratification analysis Radiother Oncol 109 2013 204 210
50. I. Fleming, J. Cooper, and D. Henson AJCC Cancer Staging Manual 5th ed. 1997 Lippincott-Raven Philadelphia
51. F. Greene, D. Page, and I. Fleming AJCC Cancer Staging Manual 6th ed. 2002 Lippincott-Raven Philadelphia
52. S.B. Edge, D.R. Byrd, and C.C. Compton AJCC Cancer Staging Manual 7th ed. 2009 Springer New York
53. M. Roach, G. Hanks, and H. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference Int J Radiat Oncol Biol Phys 65 2006 965 974
54. A. Thompson, M. Keyes, and T. Pickles Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78 2010 415 421
55. N. Mehta, M. Kamrava, and P.C. Wang Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer Int J Radiat Oncol Biol Phys 86 2013 729 733
56. I. Dos Santos Silva Case-control studies I. Dos Santos Silva, Cancer Epidemiology: Principles and Methods 1999 IARC Lyon 189 212
57. M. Caliendo, and S. Kopeinig Some practical guidance for the implementation of propensity score matching J Econ Surv 22 2008 31 72
58. M. Lunt Selecting an appropriate caliper can be essential for achieving good balance with propensity score matching Am J Epidemiol 179 2013 226 235
59. E. Stuart Matching methods for causal inference: A review and a look forward Stat Sci 25 2010 1 21
60. P. Austin Some methods of propensity-score matching had superior performance to others: Results of an empirical investigation and Monte Carol simulations Biom J 51 2009 171 184
61. K. Imai, G. King, and E. Stuart Misunderstandings between experimentalists and observationalists about causal inference J R Stat Soc A 171 2008 481 502
62. P. Austin, P. Grootendorst, and G. Anderson A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: A Monte Carlo study Stat Med 26 2007 734 753
63. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123